# Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis

> **NCT07204093** · — · ACTIVE_NOT_RECRUITING · sponsor: **Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico** · enrollment: 138 (estimated)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Drospirenone 4 mg orally
- **DRUG:** Dienogest 2 mg orally

## Key facts

- **NCT ID:** NCT07204093
- **Lead sponsor:** Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-08-11
- **Primary completion:** 2026-02
- **Final completion:** 2026-02
- **Target enrollment:** 138 (ESTIMATED)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07204093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07204093, "Ultra-Safe Hormonal Strategy: Transdermal Estradiol Added to Progestins for Endometriosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07204093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*